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Abstract
Background. Veterans with significant chronic pain from musculoskeletal disorders are at risk of substance misuse.
Veterans whose condition is the result of military service may be eligible for a disability pension. Department of
Veterans Affairs compensation examinations, which determine the degree of disability and whether it was connected
to military service, represent an opportunity to engage Veterans in pain management and substance use treatments. A
multisite randomized clinical trial is testing the effectiveness and cost-effectiveness of Screening, Brief Intervention,
and Referral to Treatment for Pain Management (SBIRT-PM) for Veterans seeking compensation for musculoskeletal
disorders. This telephone-based intervention is delivered through a hub-and-spoke configuration. Design. This study is
a two-arm, parallel-group, 36-week, multisite randomized controlled single-blind trial. It will randomize 1,100
Veterans experiencing pain and seeking service-connection for musculoskeletal disorders to either SBIRT-PM or
usual care across eight New England VA medical centers. The study balances pragmatic with explanatory methodo-
logical features. Primary outcomes are pain severity and number of substances misused. Nonpharmacological pain
management and substance use services utilization are tracked in the trial. Summary. Early trial enrollment targets
were met across sites. SBIRT-PM could help Veterans, at the time of their compensation claims, use multimodal
The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine.
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pain treatments and reduce existing substance misuse. Strategies to address COVID-19 pandemic impacts on the
SBIRT-PM protocol have been developed to maintain its pragmatic and exploratory integrity.
Key Words: Pain; Substance Use; Musculoskeletal Disorders; Veterans; Compensation and Pension
Background and Rationale
More than half of post-9/11 Veterans have a musculo-
skeletal disorder (MSD) with significant chronic pain [1].
These Veterans are at high risk of developing alcohol and
other substance use disorders [1]. Individuals with
chronic pain and a substance use disorder show worse
treatment outcomes for both conditions [2, 3].
MSDs frequently originate from disabling injuries sus-
tained while in military service. During separation from
active military duty or after separation, Veterans may
seek compensation for these disabilities by receiving a
specialized compensation clinic examination. This exam-
ination determines which conditions are connected to
their military service. Conditions are assigned a service-
connection rating between 0% and 100%, with higher
ratings indicating more impairment and, consequently,
more financial compensation and prioritization for
health care in the Veterans Health Administration
(VHA) [4].
The number of Veterans receiving MSD-related com-
pensation is large. As of 2019, 1,063,781 awards for
lumbosacral or cervical strain had been approved for liv-
ing compensation recipients, and during 2019, 76,050
new claims for these conditions were awarded [5].
Efforts to connect these Veterans to VHA services around
the time of their MSD-related compensation examina-
tions could improve their functioning and quality of life
through engagement in the comprehensive array of multi-
modal nonpharmacological pain management and sub-
stance use treatments available at VA or in the
community. Furthermore, focusing on post-9/11
Veterans with MSD, rather than older Veterans, provides
an opportunity for early intervention before their pain
and substance misuse becomes more chronic and difficult
to treat.
Rosen and colleagues tested the efficacy of such an ap-
proach in a small clinical trial [6]. Veterans seeking com-
pensation for service-connected MSD who had chronic
pain and substance misuse were randomized to a motiva-
tional interviewing–based [7] Screening, Brief
Intervention, and Referral to Treatment for pain manage-
ment and substance misuse (SBIRT-PM), pain manage-
ment counseling only, or usual care (UC). Both brief
counseling interventions offered an initial 60-minute in-
person session, with up to two 5- to 10-minute subse-
quent phone calls over 4 weeks. Follow-up data were col-
lected at 12 weeks. Results showed that higher
proportions of Veterans in SBIRT-PM and the pain man-
agement–only conditions received VA pain treatment
than those in UC (51% vs 27%, respectively). In addi-
tion, Veterans in SBIRT-PM, with its added focus on re-
ducing substance misuse, had significantly lower rates of
self-reported problematic substance use than those of
Veterans assigned to pain management counseling only
or UC. Mean pain severity did not change over time, re-
gardless of condition. A longer follow-up period may
have been needed to detect effects of newly utilized pain
treatments.
To scale up clinical innovations such as SBIRT-PM,
VA often uses a hub-and-spoke approach, wherein a
“hub” site deploys its expertise and administrative
resources to “spoke” or satellite sites within the health
care system. Examples include VA Epilepsy Centers of
Excellence [8], Specialty Care Access Networks–
Extension for Community Healthcare Outcomes (SCAN-
ECHO) [9], and the use of Veterans Integrated Service
Networks (VISN) to oversee health care policy and ser-
vice delivery of medical centers in designated regions
[10]. Compared with a non-networked model, a hub-
and-spoke approach permits specialized personnel to
serve multiple sites and is more cost-effective from a hos-
pital [11] and societal perspective [12].
The present article describes the study protocol for a
multisite randomized clinical trial that tests the effective-
ness and cost-effectiveness of SBIRT-PM, compared with
UC, for claim-seeking Veterans with MSD-related
chronic pain. For pragmatic purposes, the trial includes a
broad range of Veterans who have chronic pain with or
without substance misuse. It also uses a hub-and-spoke
configuration within the New England VISN involving
phone-based recruitment and assessment of participants




The present study has three main objectives. Objective 1
is to determine whether SBIRT-PM is more effective than
UC in reducing pain severity and, secondarily, reducing
pain interference with life activities, reducing overall
pain, increasing nonpharmacological pain management
service utilization, and improving health-related quality
of life. We hypothesize that SBIRT-PM will be more ef-
fective than UC and that nonpharmacological pain man-
agement service utilization will mediate pain outcomes.
Objective 2 is to determine whether SBIRT-PM is more
effective than UC in reducing the number of misused sub-
stances requiring intervention and, secondarily, reducing
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use severity for individual substances. We hypothesize
that SBIRT-PM will be more effective than UC and that
nonpharmacological pain management and substance
use service utilization will mediate reduced substance
use. Objective 3 is to determine the cost-effectiveness and
budget impact of SBIRT-PM relative to UC. We hypothe-
size that SBIRT-PM, relative to UC, will be a cost-
effective use of VA and societal resources and have no
net budgetary impact on local VA resources.
Overall Design
This study is a two-arm, parallel-group, 36-week, multi-
site randomized controlled single-blind trial (see
Supplementary Data). We will randomize 1,100 Veterans
applying for service-connected, MSD-related compensa-
tion to either SBIRT-PM or UC across eight VA medical
centers in New England. All study methods have been
reviewed and approved by the VA Central Institutional
Review Board and Yale University Human Investigation
Committee and have been published on
ClinicalTrials.gov (NCT04062214). The study balances
pragmatic with explanatory features, as illustrated on the
Pragmatic Explanatory Continuum Indicator Summary
(PRECIS-2) wheel (see Supplementary Data) [13, 14].
Several features make the trial pragmatic (i.e., testing
SBIRT-PM in routine practice). The trial occurs in eight
sites across New England rather than a single site, allow-
ing for inclusion of a broad range of Veterans who have
chronic pain with or without substance misuse. Data
gathering includes primary outcomes (pain, substance
use, and cost) of importance to Veterans, providers,
administrators, and policy makers and is completed
through review of the electronic health record (EHR).
Moreover, the trial tests the effectiveness of SBIRT-PM
compared with its real-world alternative, UC, rather than
an active treatment control. Simultaneously, the trial has
several explanatory features (i.e., testing SBIRT-PM with
more internal controls). It relies on research staff to re-
cruit and assess study-eligible participants. Counselors
were hired to deliver SBIRT-PM, rather than existing
medical center staff. In addition, the trial includes
monthly SBIRT-PM adherence monitoring and supervi-
sion with performance feedback and coaching to main-
tain the integrity of the intervention.
Study Population
Participant inclusion criteria are: 1) post-9/11 Veterans
who have applied for service-connected, MSD-related
(specified as back, neck, shoulder, or knee) compensation
as ascertained from a filed claim; 2) a score of 4 on the
Brief Pain Inventory’s Pain Severity subscale (threshold
for moderately severe pain) [15]; and 3) access to a
phone. Exclusion criteria are: 1) receipt of >2 nonphar-
macological pain VA treatment modalities within the
prior 12 weeks (because a goal of the trial is to increase
engagement in such treatments); 2) self-reported inability
to participate during the study enrollment period; and 3)
participation in another NIH-DOD-VA Pain
Management Collaboratory study [16] at time of study
recruitment, as evidenced by an EHR alert.
Screening, Recruitment, and Randomization
Research staff identify Veterans scheduled for MSD-
related compensation examinations by reviewing EHR
and compensation clinic information. Next, Veterans
with post-9/11 military service receive a recruitment let-
ter and study information sheet; the letter and informa-
tion sheet explain basic study details and provide
instructions on how Veterans can opt out (by phone) of
further outreach from research staff. Research staff call
Veterans who do not opt out and explain the study, fur-
ther screen for eligibility, and complete voluntary in-
formed consent for study-eligible and interested
Veterans. Veterans can enroll up to 6 weeks after recruit-
ment materials are mailed to permit enough time for par-
ticipant recruitment around the time of their
examinations.
Next, participants complete baseline study assess-
ments by phone, and then research staff provide the study
director with key balancing variables, namely sex (male/
female), race (White, Black, Other), ethnicity (Hispanic/
Non-Hispanic), and any self-reported illicit drug use (in-
cluding cannabis) within 90 days (Yes/No), for stratified
randomization of participants to SBIRT-PM or UC
through the use of a computerized urn program [17].
Illicit drug use is a balancing variable because unlike al-
cohol or tobacco, the efficacy of SBIRT for illicit drug
use has been equivocal and site and population depen-
dent [18]. The study director runs the randomization pro-
gram and notifies SBIRT-PM counselors to contact
participants assigned to SBIRT-PM and initiate the inter-
vention; UC participants receive subsequent contact from
research staff only to complete follow-up study assess-
ments. Research staff conducting assessments are blinded
to the participants’ condition.
Participating Sites
The study is occurring at VA New England Healthcare
System (VISN1), a network of eight medical centers in
six New England states: Massachusetts (in the cities of
Boston, Bedford, and Leeds), Connecticut (West Haven),
Maine (Togus), Vermont (White River Junction), New
Hampshire (Manchester), and Rhode Island
(Providence). Each site provides MSD-related compensa-
tion examinations and several nonpharmacological pain,
substance use, and mental health treatments. All sites de-
liver treatment according to a Stepped Care Model of
Chronic Pain [19–21], which emphasizes multimodal
care within a biopsychosocial framework and involves
primary care and patient-aligned care teams (PACTs) as
the nexus of pain treatment, secondary consultation with
specialty care and evaluation, and tertiary
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interdisciplinary pain centers. Every medical center has
an interdisciplinary pain team, physical therapy, acu-
puncture, yoga, and cognitive behavioral therapy for
chronic pain. Many facilities also have pain education
workshops, chiropractic care, nutrition consultations, oc-
cupational therapy, physiatry, rheumatology, Tai Chi,
and other complementary and integrated health options
supported by the VHA Whole Health Initiative [22].
Also, community care treatment referrals, funded by VA,
are available to VA-enrolled Veterans [23]. A local prin-
cipal investigator helps research staff implement the trial.
Interventions: SBIRT-PM and UC
SBIRT-PM is a manualized, motivational interviewing–
based [7], five-session, phone-delivered intervention,
with four sessions occurring over an initial 12-week pe-
riod and an additional booster session offered between
weeks 12 and 32. All sessions aim to motivate Veterans
to engage in multimodal nonpharmacological pain care
and reduce substance misuse when present. Counselors
from VA Connecticut provide SBIRT-PM remotely to
Veterans throughout VISN1.
The first 1-hour session includes several elements:
1) an orientation that describes the counseling and
explains its separation from service-connection claim
determinations; 2) empathic exploration of the Veteran’s
MSD, pain experiences, and motivations for pain care;
3) psychoeducation about the benefits of multimodal pain
care, judicious use of non-opioid medications, and avail-
able local pain management services and mental health
treatments for conditions, such as depression or posttrau-
matic stress disorder, that might exacerbate chronic pain;
4) screening for substance misuse, including misuse of pre-
scription medications, and motivational enhancement to
change behaviors related to positive screens; and 5) for
those committed to engaging in services or addressing sub-
stance misuse, making plans to achieve these goals.
Over the subsequent 12 weeks, counselors hold up to
three additional 20-minute phone sessions with partici-
pants (about once per month) to check on their goal
achievement and continue motivational enhancement for
multimodal pain treatment and reduced substance mis-
use. Counselors offer one more 20-minute session during
weeks 12–32 to sustain participants’ motivation to en-
gage in available pain and substance use services and ad-
dress ongoing obstacles (e.g., transportation, relocation)
or health care system changes (e.g., COVID-19 impacts).
SBIRT-PM also includes coordination between the
counselors and primary care providers to support partici-
pants’ improved pain and substance use treatment out-
comes. Counselors communicate with primary care
providers about the participants’ interests in services pri-
marily through notes placed in the EHR. These notes are
read by primary care providers or health professionals,
who may refer patients to services. Counselors also glean
important information from the EHR (e.g., checking
whether a primary care provider made a referral, review-
ing notes indicating engagement with services) to inform
their counseling sessions.
Consistent with the national VA Evidence-Based
Practice training model [24], SBIRT-PM counselors re-
ceived an initial 2.5-day didactic and experiential work-
shop, followed by a certification process (i.e., audio-
recorded practice phone sessions until adequate profi-
ciency had been achieved) conducted by this article’s first
author (SM), an SBIRT-PM expert. All trial sessions are
audio recorded; the SBIRT-PM expert reviews two ses-
sions per month per counselor and holds monthly group
supervision meetings to provide performance feedback
and coaching. Independent verification of SBIRT integ-
rity will occur through the use of the Independent Tape
Rater Scale [25].
Veterans assigned to UC are contacted by research
staff for research study assessments only. Veterans who
apply for service-connected compensation do not typi-
cally receive orientation to the VA health care system or
referral to treatment as part of the claims process.
Baseline and Follow-Up Procedures
The trial uses several measures [15, 26–35] at baseline
and at the 12- and 36-week follow-up assessment points
(see Supplementary Data for description of measures and
schedule of assessments). Data are entered directly into
the secure VA Research Electronic Data Capture
(REDCap) data collection tool by research staff or are
extracted from EHR or VA datasets.
Costs will be assessed for activities needed to replicate
SBIRT-PM if it were adopted in routine practice. These
activities include identifying and recruiting eligible
Veterans, preparing for counseling, delivering counseling,
following up and making referrals, and training and su-
pervision. Micro-cost estimates will be based on study
data on SBIRT-PM encounters, staff reports of time, and
data on labor cost and overhead from the VA Managerial
Cost Accounting (MCA) system. The cost of VA MSD-
related care, pain medications, and other health services
will be obtained from the MCA system, the claims data
of the VA Community Care program, and patient self-
report. The cost of non-VA MSD care will be estimated
on the basis of self-reported quantities of pain treatments
used and VA unit costs or published estimates of unit
costs per treatment service.
Primary and Secondary Outcomes
The two primary outcomes are the Brief Pain Inventory
pain severity subscale score [15] and the number of sub-
stances that either are above the “no-intervention”
threshold in the Alcohol, Smoking, and Substance
Involvement Test (ASSIST) [29] or found in toxicological
analysis of nail clippings. The ASSIST generates an ordi-
nal severity score based on self-reported negative conse-
quences from individual substances used in the prior 3
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months; scores above 3 indicate a need for intervention,
apart from alcohol, which requires a score above 10.
When a positive toxicology result disagrees with a self-
report of no use, the middle value on the ordinal scale of
the ASSIST will be used as the primary substance use out-
come. Obtaining both self-report and toxicology data to
determine substance use is a recommended best practice,
particularly for patients seeking treatment for chronic
pain who have been found to underreport opioid and
other substance use [36].
Secondary pain outcomes include nonpharmacological
pain service utilization, pain interference with life activi-
ties (Brief Pain Inventory), overall pain (Pain, Enjoyment
of Life and General Activity scale), and health-related
quality of life (EQ-5D-5L). Nonpharmacological pain
management service utilization will be summed across
modalities (emergency/urgent pain care, primary care,
surgery, spinal cord stimulator, injections, transcutane-
ous electrical nerve stimulation, acupuncture, dry nee-
dling, acupressure, manipulation, massage therapy, yoga,
reiki, biofeedback, education, counseling for pain, relax-
ation techniques, meditation/mindfulness, hypnosis/hyp-
notherapy, exercises/stretches, and other treatments not
already mentioned). In addition, we will evaluate the fre-
quency of use of each of these modalities over the prior
3 months. Secondary substance use outcomes will include
severity measures for individual substances generated by




With two primary outcomes (change in pain severity
from the Brief Pain Inventory and change in the number
of substances requiring intervention), Bonferroni correc-
tion was used to generate P values of 0.025 for the sam-
ple size calculations for each outcome. The sample size
was calculated for power¼0.90 by using two-tailed
alpha¼0.025 and an expected effect size of d¼0.25 for
pain severity, with 27% attrition, the rate observed in
our previous pilot work [6]. The calculation is as follows:
400 per intervention condition (SBIRT-PM and UC) di-
vided by “1 – loss to follow-up” (73%)¼5482
groups¼1,096. The planned randomized sample size is
1,100, with sample selection at each site proportional to
the size of the site. For substance use, the proportion con-
verting to low risk on at least one substance in the treat-
ment group per our pilot study [6] was estimated as
27%, and in UC it was estimated as 10%. Attrition was
set at 27%. For 90% power with the alpha¼0.025, the
calculations resulted in a sample size of 128 per group di-
vided by “1 – loss to follow-up” (73%)¼1762
groups¼352 as the total sample size. Given that we ex-
pect at least 50% of our sample of Veterans with MSD-
related pain to have at least one substance they use prob-
lematically (based on unpublished data gathered from
our sites in preparation for this trial), we will have an ad-
equate sample in the trial to detect an effect size of 1.83
in the substance use outcome.
Analytic Methods
For clinical effectiveness analyses, descriptive statistics
(e.g., mean, standard deviation, frequency, and percent)
will be used to describe the sample and to check for base-
line differences between intervention groups. Differences
between intervention groups in the change in primary
and secondary outcome variables from baseline through
the end of the 36-week study period will be examined by
using mixed-effects models with subject as a random ef-
fect and intervention group, time, and their interaction as
fixed effects. We will explore various residual covariance
structures (e.g., unstructured, compound symmetry,
autoregressive), selecting the option with the lowest
Akaike Information Criterion. The interaction between
intervention and time will be included to test the effect of
the intervention at 12 weeks and at 36 weeks relative to
UC. For each outcome, we will estimate a Box-Cox re-
gression to identify the appropriate link function and use
the modified Park test to identify the appropriate distri-
bution assumption [37].
If there are significant differences between treatment
groups in any baseline variable, we will examine models
that adjust for potentially confounding variables, includ-
ing depression score, presence of traumatic brain injury,
mental health diagnoses, and urn covariates (sex, race,
ethnicity, and self-reported illicit drug use). Other poten-
tial confounders are distance to the nearest VA medical
center, number of pain treatment modalities used at base-
line, baseline service-connection percentage, type of
MSD claim (back, neck, knee, or shoulder), months be-
tween discharge from active service and compensation
and pension exam, and probability of study dropout.
Opioid use (misuse of prescribed agents and use of
unprescribed agents) will be examined as a mediator as
well as a tertiary outcome, given its relationship to pain.
Actual participation in SBIRT-PM (Yes/No) will be ex-
amined as a mediator of response. Finally, analyses will
examine site, sex, and race/ethnicity as moderators of
treatment response through their inclusion of tests of in-
teraction effects in models.
For cost analyses, cost of care will be measured from
the date of randomization until the end of the 36-week
follow-up. Health care cost as a continuous variable is
likely to be highly skewed; a General Linear Model will
be used to accommodate outcomes that are not normally
distributed. To identify the appropriate link function, we
will estimate a Box-Cox regression; we will use the modi-
fied Park test to identify the appropriate distribution as-
sumption [37]. These tests often result in the choice of a
log gamma regression, which accommodates the highly
skewed distribution and heteroscedastic errors of most
cost data [38].
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Cost-effectiveness analysis will be done from both the
VA health system perspective and a societal perspective
and will be measured in quality-adjusted life-years
(QALYs) [39]. The incremental cost-effectiveness ratio
will be the ratio of the difference in cost (mean SBIRT-
PM cost less mean UC cost) divided by the difference in
outcomes (QALYs in SBIRT-PM group less QALYs in
UC group). Using bootstrap sampling, we will plot a
cost-effectiveness acceptability curve of the P values (per-
centage of replicates not cost-effective) over the range of
$10,000 to $1,000,000 per QALY, which covers all plau-
sible critical values for cost-effectiveness in the U.S.
health care system. Decision makers can use cost-
effectiveness acceptability curves to determine whether
benefits justify the costs. If SBIRT-PM produces a QALY
for less than $100,000 over 36 weeks, SBIRT-PM will be
considered worth adopting.
Finally, we will follow guidelines for budget impact
analysis developed by the International Society for
Pharmacoeconomics and Outcomes Research [40]. We
will determine the 36-week direct costs of SBIRT-PM ex-
clusive of overhead on the basis of our micro-costing pro-
cedures and MCA data. We will consider the effect of the
intervention on Veteran enrollments, which affect bud-
getary allocations to the regional network. The goal is to
find the cost of the intervention net of its impact on these
revenues. This represents the budget impact from the
point of view of the regional administrator, who must de-
cide whether to sustain SBIRT-PM after the trial has
concluded.
Procedures for Handling Missing Data
The study will minimize missing data by using regular re-
minder calls and by calling contacts of Veterans who
miss appointments. Some missingness nevertheless may
occur. It may not be completely at random. Participants
may be less likely to share more sensitive information,
such as use of illicit substances. In addition, on the basis
of our previous study [6], we anticipate that there might
be differences in follow-up rates in the two trial arms,
with Veterans in UC likely to drop out more frequently.
Patterns of missingness will be examined by each individ-
ual covariate in the data (univariate, monotone, or non-
monotone). Chi-square and t tests will be run to see if
missingness is related to other baseline variables in the
analysis (e.g., intervention status, substance use).
Multiple imputation will be used in the case of variables
missing either completely at random or at random. To re-
duce the likelihood of missing not at random, the multi-
ple imputation model will include “auxiliary variables”
that are highly correlated with both the variable that has
missing data and the probability that the variable is miss-
ing. Sensitivity analyses will be conducted as part of the
multiple imputation procedure (PROC MI) in SAS 9.4
(SAS Institute Inc., Cary, NC, USA). All statistical tests
will be based on analysis of variance between the multi-
ple imputations.
Implementation and Dissemination
The VISN1 Director will be briefed on trial findings. At a
national level, we will share our findings with VA opera-
tional leaders in the National Pain Management Program
Office and the National Pain Research Working Group,
which includes pain investigators who teleconference reg-
ularly to identify priorities for pain research and develop
collaborative projects. Moreover, we will share the
results with the Veterans Benefits Administration leader-
ship, including the Disability Examination Management
Office, which sets policy for compensation examination
procedures, as well as the Program Policy
Implementation Office of Mental Health Services, which
oversees the conduct of service-connection examinations
in VA.
Discussion
Trial recruitment began on October 23, 2019, and is
expected to last 32 months. Enrolled participants at the
time of the study protocol manuscript submission
(n¼ 184) have shown substantial pain symptomatology
(mean past week Brief Pain Inventory pain severity sub-
scale score¼5.3; standard deviation¼1.2), and more than
half of the sample (53%) has reported problematic use of
at least one substance in need of intervention.
Approximately 83% of participants assigned to SBIRT-
PM received at least one counseling session. There have
been no serious study-related adverse events to date.
These early indicators bode well for the trial to reach the
targeted sample and safely test the effectiveness and cost-
effectiveness of SBIRT-PM.
The trial has several strengths, including a large tar-
geted sample size; multisite randomized controlled de-
sign; pragmatic measures of pain, substance use, and
costs; and long follow-up period to detect treatment
effects. Moreover, SBIRT-PM is a simple and flexible in-
tervention delivered by phone to Veterans in a VA re-
gional network. Providing SBIRT-PM to Veterans at the
time of their compensation claims could foster their use
of multimodal pain treatments and reduce existing sub-
stance misuse early. If cost-effective, SBIRT-PM could be
implemented in other regional VA health care systems.
Challenges to conducting the trial have been related
largely to the worldwide COVID-19 pandemic.
Beginning in March 2020, most in-person VA and
community-based pain management and substance use
services were halted and, when possible, converted to vir-
tual delivery. In addition, because of coronavirus health
risks, there was a reduction in the number of Veterans fil-
ing compensation claims and/or having scheduled exams.
Because the study is conducted entirely by phone, the
trial has continued uninterrupted, albeit at reduced
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recruitment volume. Consulting the VA Pain
Management Collaboratory [16], we amended the
SBIRT-PM protocol to include a COVID-19 question-
naire (developed within the Phenotypes Workgroup) to
identify how the pandemic affects participants’ health,
social determinants of health, and access to health care.
We also have anticipated (with input from the
Biostatistics Workgroup) necessary adjustments to our
analytic methods to accommodate potential pandemic
effects that vary over time on primary and secondary out-
comes. Furthermore, we have modified the SBIRT-PM
intervention to permit discussion of pandemic-related
stressors and updated information about available virtual
and self-help pain and substance use services accessible to
Veterans at all sites. Finally, we added the booster session
between weeks 12 and 32 as an additional opportunity to
counsel Veterans when services are more likely to restart.
With the VA and community health care systems now
“reopening,” we anticipate that recruitment will gradu-
ally resume to pre-pandemic levels, given the backlog of
Veterans needing compensation examinations and treat-
ment. Ongoing collaboration and consultation with our
site principal investigators, VA Pain Management
Collaboratory workgroups, VA partners, and Data
Safety and Monitoring Board will be essential to main-
tain the pragmatic and exploratory integrity of the
SBIRT-PM study protocol moving forward.
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